YAP1 and its fusion proteins in cancer initiation, progression and therapeutic resistance.

YAP1 and its fusion proteins in cancer initiation, progression and therapeutic resistance.
Dev Biol. 2021 Jan 08;:
Authors: Szulzewsky F, Holland EC, Vasioukhin V
Abstract
YAP1 is a transcriptional co-activator whose activity is controlled by the Hippo signaling pathway. In addition to important functions in normal tissue homeostasis and regeneration, YAP1 has also prominent functions in cancer initiation, aggressiveness, metastasis, and therapy resistance. In this review we are discussing the molecular functions of YAP1 and its roles in cancer, with a focus on the different mechanisms of de-regulation of YAP1 activity in human cancers, including inactivation of upstream Hippo pathway tumor suppressors, regulation by intersecting pathways, miRNAs, and viral oncogenes. We are also discussing new findings on the function and biology of the recently identified family of YAP1 gene fusions, that constitute a new type of activating mutation of YAP1 and that are the likely oncogenic drivers in several subtypes of human cancers. Lastly, we also discuss different strategies of therapeutic inhibition of YAP1 functions.
PMID: 33428889 [PubMed - as supplied by publisher]

Source: Developmental Biology - January 8, 2021 Category: Biology Authors: Szulzewsky F, Holland EC, Vasioukhin V Tags: Dev Biol Source Type: research